Michael Schulz

Title: Michael Schulz: Innovator in Cancer Therapy

Introduction

Michael Schulz is a notable inventor based in Aschheim, Germany. He has made significant contributions to the field of cancer therapy through his innovative research and development of new biologically active compounds.

Latest Patents

Schulz holds a patent for "Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy." This patent describes compounds that inhibit the cellular formation of niacinamide mononucleotide, which is an essential intermediate in the NAD(P) biosynthesis within cells. These compounds have the potential to serve as active ingredients in pharmaceutical compositions aimed at treating cancers, leukemias, or for immunosuppression. Additionally, the patent outlines screening methods that can be utilized to detect these active compounds and examine specific cell types for their dependency on niacinamide as a precursor for NAD synthesis. He has 1 patent to his name.

Career Highlights

Michael Schulz is currently associated with Klinge Pharma GmbH, where he continues to advance his research in the pharmaceutical field. His work focuses on developing innovative solutions for cancer treatment, showcasing his commitment to improving patient outcomes.

Collaborations

Schulz collaborates with esteemed colleagues, including Elfi Biedermann and Rolf Eisenburger, who contribute to his research endeavors and help drive innovation in cancer therapy.

Conclusion

Michael Schulz is a pioneering inventor whose work in cancer therapy is making a significant impact. His innovative compounds and research methodologies hold promise for advancing treatment options for patients facing cancer and related conditions.